Alexander Terence Faje, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperprolactinemia | 4 | 2022 | 124 | 1.940 |
Why?
|
| Anorexia Nervosa | 11 | 2022 | 1361 | 1.440 |
Why?
|
| Prolactinoma | 3 | 2022 | 114 | 1.370 |
Why?
|
| Pituitary Neoplasms | 5 | 2022 | 1323 | 0.990 |
Why?
|
| Pituitary Gland | 3 | 2016 | 635 | 0.890 |
Why?
|
| Dopamine Agonists | 2 | 2016 | 352 | 0.800 |
Why?
|
| Bone Density | 10 | 2022 | 3551 | 0.730 |
Why?
|
| Hypopituitarism | 2 | 2019 | 250 | 0.540 |
Why?
|
| Pituitary Diseases | 2 | 2024 | 135 | 0.530 |
Why?
|
| Bone and Bones | 5 | 2019 | 2568 | 0.530 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2020 | 1935 | 0.480 |
Why?
|
| Melanoma | 3 | 2018 | 5709 | 0.460 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 20 | 0.450 |
Why?
|
| Polyuria | 1 | 2013 | 37 | 0.440 |
Why?
|
| Glucocorticoids | 3 | 2018 | 2161 | 0.430 |
Why?
|
| Body Composition | 5 | 2019 | 2426 | 0.410 |
Why?
|
| Cysts | 1 | 2016 | 681 | 0.370 |
Why?
|
| Prolactin | 3 | 2022 | 625 | 0.360 |
Why?
|
| Acromegaly | 4 | 2020 | 310 | 0.360 |
Why?
|
| Body Weight | 5 | 2016 | 4618 | 0.360 |
Why?
|
| Dacarbazine | 1 | 2013 | 559 | 0.350 |
Why?
|
| Fractures, Bone | 4 | 2022 | 2046 | 0.340 |
Why?
|
| Bone Development | 1 | 2013 | 472 | 0.340 |
Why?
|
| Bone Remodeling | 2 | 2015 | 581 | 0.330 |
Why?
|
| Adolescent Development | 1 | 2013 | 282 | 0.330 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 617 | 0.330 |
Why?
|
| Human Growth Hormone | 3 | 2011 | 642 | 0.320 |
Why?
|
| Health | 1 | 2012 | 398 | 0.320 |
Why?
|
| Estradiol | 2 | 2013 | 1937 | 0.320 |
Why?
|
| Aneurysm | 1 | 2012 | 337 | 0.310 |
Why?
|
| Adipose Tissue | 4 | 2022 | 3313 | 0.300 |
Why?
|
| Carotid Arteries | 1 | 2012 | 941 | 0.290 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2012 | 842 | 0.280 |
Why?
|
| Immunotherapy | 4 | 2024 | 4652 | 0.270 |
Why?
|
| Absorptiometry, Photon | 7 | 2022 | 1738 | 0.260 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 1651 | 0.260 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 877 | 0.250 |
Why?
|
| Postmenopause | 1 | 2014 | 2513 | 0.240 |
Why?
|
| Radius | 2 | 2019 | 441 | 0.240 |
Why?
|
| Lumbar Vertebrae | 1 | 2013 | 1879 | 0.220 |
Why?
|
| Bone Marrow | 3 | 2022 | 2911 | 0.200 |
Why?
|
| Tibia | 2 | 2019 | 1070 | 0.200 |
Why?
|
| Finite Element Analysis | 4 | 2019 | 438 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 9177 | 0.180 |
Why?
|
| Thyroiditis | 1 | 2021 | 86 | 0.180 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2016 | 618 | 0.180 |
Why?
|
| Hypokalemia | 1 | 2021 | 153 | 0.180 |
Why?
|
| Adenoma | 2 | 2021 | 2163 | 0.170 |
Why?
|
| Hyponatremia | 1 | 2021 | 279 | 0.160 |
Why?
|
| Diabetes Insipidus | 1 | 2019 | 144 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 5821 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2021 | 370 | 0.160 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2016 | 1988 | 0.150 |
Why?
|
| Humans | 42 | 2024 | 761596 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2013 | 7859 | 0.130 |
Why?
|
| Retrospective Studies | 10 | 2022 | 80647 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2022 | 1892 | 0.130 |
Why?
|
| Female | 28 | 2022 | 392705 | 0.130 |
Why?
|
| Case-Control Studies | 6 | 2021 | 22176 | 0.130 |
Why?
|
| Adult | 20 | 2022 | 221210 | 0.120 |
Why?
|
| Premenopause | 1 | 2019 | 1039 | 0.120 |
Why?
|
| Oxytocin | 1 | 2019 | 402 | 0.120 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 11904 | 0.120 |
Why?
|
| Fasting | 1 | 2021 | 1603 | 0.120 |
Why?
|
| Middle Aged | 18 | 2021 | 220921 | 0.120 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2013 | 42 | 0.110 |
Why?
|
| Receptors, Prolactin | 1 | 2013 | 16 | 0.110 |
Why?
|
| Specialization | 1 | 2018 | 778 | 0.110 |
Why?
|
| Chemical Phenomena | 1 | 2013 | 507 | 0.110 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 26129 | 0.100 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2015 | 179 | 0.100 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2012 | 11 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2018 | 1187 | 0.100 |
Why?
|
| Porosity | 1 | 2013 | 349 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2018 | 2643 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 13642 | 0.100 |
Why?
|
| Adolescent | 9 | 2016 | 88326 | 0.090 |
Why?
|
| Risk | 2 | 2014 | 9610 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8527 | 0.090 |
Why?
|
| Glucose Tolerance Test | 2 | 2011 | 1178 | 0.090 |
Why?
|
| Saliva | 1 | 2015 | 828 | 0.090 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2012 | 168 | 0.090 |
Why?
|
| Aftercare | 1 | 2016 | 914 | 0.090 |
Why?
|
| Young Adult | 9 | 2019 | 59260 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 14608 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2013 | 616 | 0.090 |
Why?
|
| Body Mass Index | 4 | 2020 | 12953 | 0.080 |
Why?
|
| Male | 17 | 2021 | 360846 | 0.080 |
Why?
|
| Fibroblast Growth Factors | 1 | 2015 | 867 | 0.080 |
Why?
|
| Corticotrophs | 1 | 2008 | 3 | 0.080 |
Why?
|
| Massachusetts | 2 | 2021 | 8833 | 0.080 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 321 | 0.080 |
Why?
|
| Lipolysis | 1 | 2010 | 212 | 0.080 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2008 | 72 | 0.080 |
Why?
|
| Astrocytoma | 1 | 2013 | 775 | 0.080 |
Why?
|
| Aged | 9 | 2021 | 169310 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 1069 | 0.080 |
Why?
|
| Prognosis | 3 | 2021 | 29629 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2015 | 1819 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2012 | 751 | 0.070 |
Why?
|
| Reference Values | 2 | 2011 | 4920 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 10766 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2013 | 2919 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2012 | 2601 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2010 | 6391 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2018 | 10090 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1853 | 0.060 |
Why?
|
| Amenorrhea | 2 | 2019 | 483 | 0.060 |
Why?
|
| Neoplasms | 3 | 2024 | 22173 | 0.060 |
Why?
|
| Obesity | 2 | 2019 | 12947 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2016 | 3728 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 12341 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9280 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2020 | 1814 | 0.050 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2013 | 1642 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 2898 | 0.050 |
Why?
|
| Thermotoga maritima | 1 | 2001 | 13 | 0.050 |
Why?
|
| Anxiety | 1 | 2016 | 4573 | 0.050 |
Why?
|
| Time Factors | 3 | 2020 | 39969 | 0.050 |
Why?
|
| Peptides | 1 | 2013 | 4358 | 0.050 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2001 | 68 | 0.050 |
Why?
|
| Electrolytes | 1 | 2021 | 274 | 0.050 |
Why?
|
| Radiography | 1 | 2012 | 6965 | 0.040 |
Why?
|
| Sex Factors | 1 | 2014 | 10554 | 0.040 |
Why?
|
| DNA Glycosylases | 1 | 2001 | 125 | 0.040 |
Why?
|
| Boston | 1 | 2013 | 9327 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 4062 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2019 | 125 | 0.040 |
Why?
|
| Appetite Stimulants | 1 | 2018 | 14 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 36426 | 0.040 |
Why?
|
| Femur Neck | 1 | 2019 | 314 | 0.040 |
Why?
|
| Age Factors | 1 | 2014 | 18399 | 0.040 |
Why?
|
| Weight-Bearing | 1 | 2019 | 532 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 15733 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 58984 | 0.030 |
Why?
|
| Sodium | 1 | 2021 | 1588 | 0.030 |
Why?
|
| Psychopathology | 1 | 2019 | 432 | 0.030 |
Why?
|
| Risk Factors | 2 | 2014 | 74213 | 0.030 |
Why?
|
| Ghrelin | 1 | 2018 | 252 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2020 | 1596 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2013 | 11530 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2018 | 242 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 701 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2002 | 1608 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20568 | 0.030 |
Why?
|
| Spine | 1 | 2019 | 1118 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 9032 | 0.020 |
Why?
|
| Mesentery | 1 | 2012 | 202 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 2917 | 0.020 |
Why?
|
| Outpatients | 1 | 2018 | 1597 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 573 | 0.020 |
Why?
|
| Remission Induction | 1 | 2015 | 2397 | 0.020 |
Why?
|
| Inpatients | 1 | 2021 | 2548 | 0.020 |
Why?
|
| Apamin | 1 | 2008 | 17 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2021 | 64685 | 0.020 |
Why?
|
| Corticosterone | 1 | 2008 | 305 | 0.020 |
Why?
|
| Weight Gain | 1 | 2018 | 2348 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 1835 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39106 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2008 | 361 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2019 | 6241 | 0.020 |
Why?
|
| Vitamin D | 1 | 2019 | 3303 | 0.020 |
Why?
|
| Child | 1 | 2014 | 80158 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 4948 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 2576 | 0.010 |
Why?
|
| Animals | 2 | 2013 | 168475 | 0.010 |
Why?
|
| Recurrence | 1 | 2015 | 8466 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2002 | 352 | 0.010 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 2001 | 35 | 0.010 |
Why?
|
| Staurosporine | 1 | 2002 | 242 | 0.010 |
Why?
|
| Hospitalization | 1 | 2021 | 10721 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 360 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 2001 | 242 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 2002 | 220 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 2001 | 344 | 0.010 |
Why?
|
| Enzyme Stability | 1 | 2001 | 219 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2002 | 370 | 0.010 |
Why?
|
| Alkaloids | 1 | 2002 | 192 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14665 | 0.010 |
Why?
|
| Piperidines | 1 | 2008 | 1656 | 0.010 |
Why?
|
| Cyclins | 1 | 2002 | 594 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 4125 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 41495 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 54423 | 0.010 |
Why?
|
| Quality of Life | 1 | 2019 | 13367 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 8181 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 12973 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2748 | 0.010 |
Why?
|
| Pyridines | 1 | 2008 | 2875 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 1596 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 4174 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2001 | 1440 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 5035 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 6131 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 2932 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 12794 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 18966 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 20100 | 0.010 |
Why?
|
| Artifacts | 1 | 2001 | 1911 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 23741 | 0.010 |
Why?
|
| DNA Damage | 1 | 2002 | 2449 | 0.010 |
Why?
|
| DNA Repair | 1 | 2001 | 2046 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3713 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 6534 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 8321 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 2539 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13446 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2001 | 4217 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 2001 | 5112 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 17635 | 0.000 |
Why?
|
| DNA | 1 | 2002 | 7213 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2002 | 23447 | 0.000 |
Why?
|
| Mutation | 1 | 2002 | 30053 | 0.000 |
Why?
|